Skip to main content
Clinical Trials/NCT05696561
NCT05696561RecruitingNot Applicable

A Prospective, Multicenter, First in Human Clinical Trial to Evaluate the Safety and Effectiveness of the DF12 CANALOPLASTY AND TRABECULOTOMY SURGICAL SYSTEM in Subjects With Open-Angle Glaucoma Undergoing Cataract Surgery

New World Medical, Inc.3 sites in 3 countries70 target enrollmentStarted: September 9, 2025Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
70
Locations
3
Primary Endpoint
IOP change

Study Overview

Brief Summary

Clinical Trial to Evaluate the Safety and Effectiveness of a Canaloplasty Device in Subjects with Open-Angle Glaucoma

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
22 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Subjects qualifying for cataract surgery
  • •Subjects with diagnosis of open-angle glaucoma in at least one eye with unmedicated IOP of 22-34 mmHg.

Exclusion Criteria

  • •1. Patients who cannot be washed-out of IOP-lowering medications.

Arms & Interventions

Treatment with a Canaloplasty Device

Other

US. FDA Approved Canaloplasty Device

Intervention: Canaloplasty Device (Device)

Outcomes

Primary Outcomes

IOP change

Time Frame: Month12

Reduction in unmedicated IOP

Secondary Outcomes

  • IOP(Month12)
  • IOP meds(Month12)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (3)

Loading locations...

Similar Trials